| Literature DB >> 24873805 |
Hongye Zhao1, Yue Qi2, Yuefei Wang3, Yanli Wang4, Changzhu Lu3, Yu Xiao3, Bin Wang3, Wenquan Niu5.
Abstract
Serine/threonine kinase 39 (STK39) gene has been reported to be a hypertension-susceptibility gene by a recent genome-wide association study in Western populations. To validate this finding in Chinese, we focused on five well-characterized common polymorphisms in STK39 gene to examine their potential association with hypertension in a large northeastern Han population. This is a hospital-based case-control study involving 1009 hypertensive patients and 756 normotensive controls. Data were analyzed by the Haplo.Stats and multifactor dimensionality reduction (MDR) softwares. The genotype and allele distributions of rs6749447, rs3754777 and rs6433027 differed significantly between patients and controls (P < 0.001) even after the Bonferroni correction. The majority of derived haplotypes also showed remarkable differences between the two groups (P ≤ 0.001). As indicated by MDR analysis, a three-locus model including rs6749447, rs35929607 and rs3754777 was selected as the overall best with a larger testing accuracy of 0.7309 and a maximum cross-validation consistency of 10 (P < 0.001). The utility of this model was reinforced by a Logistic regression analysis. Taken together, our findings suggest the potential interactive role of STK39 gene multiple polymorphisms in the development of hypertension among northeastern Han Chinese.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24873805 PMCID: PMC4038817 DOI: 10.1038/srep05116
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The characteristics of the study population
| Characteristics | Patients (n = 1009) | Controls (n = 756) | P |
|---|---|---|---|
| Age (years) | 64.48 ± 8.53 | 64.23 ± 10.13 | 0.751 |
| Gender (males, %) | 54.31 | 53.84 | 0.843 |
| BMI (kg/m2) | 27.89 ± 6.29 | 23.18 ± 3.77 | <0.001 |
| Antihypertensive treatment (%) | 14.17% | 0% | <0.001 |
| Adjusted SBP (mmHg) | 147.31 ± 16.52 | 109.76 ± 17.97 | <0.001 |
| Adjusted DBP (mmHg) | 89.09 ± 15.92 | 71.37 ± 11.43 | <0.001 |
| Fasting glucose (mmol/L) | 6.14 ± 2.15 | 5.33 ± 1.12 | <0.001 |
| TG (mmol/L) | 1.90 ± 1.04 | 1.77 ± 0.95 | 0.024 |
| TC (mmol/L) | 4.59 ± 1.18 | 4.59 ± 0.91 | 0.995 |
| HDL-C (mmol/L) | 1.12 ± 0.32 | 1.24 ± 0.34 | <0.001 |
| BUN (mmol/L) | 5.92 ± 3.88 | 5.79 ± 4.35 | 0.557 |
| Creatinine (μmol/L) | 87.47 ± 36.79 | 81.80 ± 25.13 | 0.002 |
| Uric acid (μmol/L) | 329.12 ± 100.31 | 333.98 ± 95.54 | 0.374 |
| hsCRP (mmol/L) | 12.37 ± 41.42 | 2.21 ± 3.71 | 0.001 |
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; BUN, blood urea nitrogen; hsCRP, high sensitivity C-reactive protein.
*P values were computed by the unpaired t-test or the Mann-Whitney U test for quantitative variables and by the χ2 test for qualitative variables.
Genotype distributions and allele frequencies of five examined polymorphisms in STK39 gene between hypertensive patients and normotensive controls
| Polymorphism | Patients (n = 1009) | Controls (n = 756) | χ2 | P | |
|---|---|---|---|---|---|
| rs6749447 | CC | 488 (48.36) | 566 (74.87) | ||
| CA | 435 (43.11) | 175 (23.15) | 132.97 | <0.001 | |
| AA | 86 (8.52) | 15 (1.98) | |||
| A allele | 30.08% | 13.56% | 133.20 | <0.001 | |
| rs12692877 | GG | 710 (70.37) | 531 (70.24) | ||
| GC | 258 (25.57) | 208 (27.51) | 4.95 | 0.084 | |
| CC | 41 (4.06) | 17 (2.25) | |||
| C allele | 16.85% | 16.01% | 0.45 | 0.504 | |
| rs35929607 | AA | 309 (30.26) | 236 (31.22) | ||
| AG | 499 (49.45) | 377 (49.87) | 0.29 | 0.866 | |
| GG | 201 (19.92) | 143 (18.92) | |||
| G allele | 44.65% | 43.85% | 0.22 | 0.636 | |
| rs3754777 | GG | 562 (55.70) | 629 (83.20) | ||
| GA | 384 (38.06) | 119 (15.74) | 152.86 | <0.001 | |
| AA | 63 (6.24) | 8 (1.06) | |||
| A allele | 25.27% | 8.93% | 154.62 | <0.001 | |
| rs6433027 | CC | 178 (17.64) | 212 (28.04) | ||
| CT | 490 (48.56) | 358 (47.35) | 33.52 | <0.001 | |
| TT | 341 (33.80) | 186 (24.60) | |||
| T allele | 58.08% | 48.28% | 33.39 | <0.001 | |
*Genotypes of five examined polymorphisms were expressed as count (percentage).
**P values were computed by using the χ2 test based on the 3 × 2 contingency tables for the genotype comparison and on the 2 × 2 contingency tables for the allele comparison.
Individual risk prediction of five polymorphisms examined in STK39 gene for the occurrence of hypertension under the additive, dominant and recessive models of inheritance
| Polymorphism- (wild/mutant allele) | Adjusted | Additive model (mm vs. Wm vs. WW) | Dominant model (mm plus Wm vs. WW) | Recessive model (mm vs. Wm plus WW) |
|---|---|---|---|---|
| rs6749447-C/A | No | 2.78; 2.32–3.33; <0.001 | 3.18; 2.59–3.91; <0.001 | 4.60; 2.64–8.03; <0.001 |
| Yes | 2.41; 1.98–2.93; <0.001 | 2.71; 2.16–3.40; <0.001 | 3.91; 2.18–7.01; <0.001 | |
| rs12692877-G/C | No | 1.06; 0.89–1.27; 0.513 | 0.99; 0.81–1.22; 0.953 | 1.84; 1.04–3.27; 0.037 |
| Yes | 1.11; 0.91–1.35; 0.312 | 1.08; 0.86–1.36; 0.502 | 1.54; 0.81–2.92; 0.185 | |
| rs35929607-A/G | No | 1.03; 0.90–1.18; 0.635 | 1.03; 0.84–1.26; 0.790 | 1.07; 0.84–1.35; 0.598 |
| Yes | 0.98; 0.84–1.14; 0.802 | 1.01; 0.81–1.27; 0.919 | 0.93; 0.71–1.21; 0.574 | |
| rs3754777-G/A | No | 3.44; 2.79–4.24; <0.001 | 3.94; 3.14–4.95; <0.001 | 6.23; 2.97–13.07; <0.001 |
| Yes | 3.78; 2.99–4.77; <0.001 | 4.43; 3.42–5.74; <0.001 | 7.41; 3.39–16.17; <0.001 | |
| rs6433027-C/T | No | 1.47; 1.29–1.68; <0.001 | 1.82; 1.45–2.28; <0.001 | 1.56; 1.27–1.93; <0.001 |
| Yes | 1.44; 1.24–1.67; <0.001 | 1.63; 1.26–2.10; <0.001 | 1.64; 1.30–2.08; <0.001 |
Abbreviations: m, the mutant allele; W, the wild allele. Data were expressed as odds ratio; 95% confidence interval; P for three genetic models of inheritance. *Risk estimates were calculated with or without adjusting for age, gender and body mass index.
Frequencies of derived haplotypes (≥1% in total subjects) from five examined polymorphisms in STK39 gene between hypertensive patients and normotensive controls
| Haplotype (%) | Total (n = 1765) | Patients (n = 1009) | Controls (n = 756) | Simulated P |
|---|---|---|---|---|
| C-G-A-G-T | 13.18 | 15.68 | 11.70 | <0.001 |
| C-G-G-G-T | 12.27 | 14.59 | 10.98 | 0.001 |
| C-G-A-G-C | 12.14 | 20.67 | 5.34 | <0.001 |
| C-G-G-G-C | 11.45 | 14.38 | 8.90 | <0.001 |
| A-G-G-G-T | 8.36 | 3.13 | 11.70 | <0.001 |
| C-G-A-A-C | 8.07 | 1.78 | 13.03 | <0.001 |
| C-G-A-A-T | 6.23 | 2.76 | 8.21 | <0.001 |
| A-G-G-G-C | 4.31 | 3.14 | 5.45 | <0.001 |
| A-G-A-G-T | 4.08 | 2.55 | 5.38 | <0.001 |
| C-C-A-G-T | 3.49 | 4.76 | 2.97 | 0.001 |
| C-C-G-G-C | 2.64 | 2.70 | 2.74 | 0.115 |
| A-G-A-G-C | 2.38 | 2.33 | 2.47 | 0.393 |
| C-C-A-G-C | 1.97 | 3.60 | 0.33 | <0.001 |
| A-C-G-G-T | 1.80 | 0.73 | 2.57 | <0.001 |
| C-C-G-G-T | 1.68 | 1.57 | 1.69 | 0.460 |
| C-C-A-A-C | 1.40 | 0.27 | 2.45 | <0.001 |
| C-C-A-A-T | 1.32 | 0.54 | 1.58 | <0.001 |
*Alleles in a haplotype were in order of rs6749447, rs12692877, rs35929607, rs3754777 and rs6433027 in STK39 gene.
Global testing of all derived haplotypes with anthropometric indexes and clinical biomarkers in hypertensive patients and normotensive controls
| Patients | Controls | |||
|---|---|---|---|---|
| Characteristics | Global-stat | Global PSim | Global-stat | Global PSim |
| Age | 27.15 | 0.146 | 31.60 | 0.283 |
| Gender | 8.58 | 0.793 | 31.08 | 0.198 |
| BMI | 36.07 | 0.051 | 41.24 | 0.125 |
| Adjusted SBP | 56.12 | 0.019 | 28.86 | 0.308 |
| Adjusted DBP | 21.89 | 0.319 | 21.38 | 0.562 |
| Triglyceride | 30.50 | 0.102 | 9.40 | 0.999 |
| TC | 32.81 | 0.074 | 27.63 | 0.321 |
| HDL-C | 61.79 | 0.017 | 11.47 | 0.817 |
| Glucose | 15.64 | 0.167 | 14.85 | 0.196 |
| BUN | 27.89 | 0.047 | 5.79 | 0.713 |
| Creatinine | 9.09 | 0.606 | 6.35 | 0.836 |
| Uric acid | 20.68 | 0.363 | 8.69 | 0.839 |
| hsCRP | 5.99 | 0.705 | 7.47 | 0.719 |
Abbreviations: BMI, body mass index; SBP, systolic blood pressure, DBP, diastolic blood pressure; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; BUN, blood urea nitrogen; hsCRP, high sensitivity C-reactive protein.
Summary of MDR analysis
| Best combination of each model | Testing accuracy | Cross-validation consistency | P |
|---|---|---|---|
| rs3754777 | 0.6130 | 7 | 0.0017 |
| rs6749447, rs3754777 | 0.7150 | 10 | <0.0001 |
| rs6749447, rs35929607, rs3754777 | 0.7309 | 10 | <0.0001 |
| rs6749447, rs35929607, rs3754777, rs6433027 | 0.7329 | 10 | <0.0001 |
| rs6749447, rs12692877, rs35929607, rs3754777, rs6433027 | 0.7303 | 10 | <0.0001 |
*The overall best MDR model.